PL1791820T3 - Sposób enancjoselektywnego wytwarzania pochodnych chinoliny - Google Patents

Sposób enancjoselektywnego wytwarzania pochodnych chinoliny

Info

Publication number
PL1791820T3
PL1791820T3 PL05770221T PL05770221T PL1791820T3 PL 1791820 T3 PL1791820 T3 PL 1791820T3 PL 05770221 T PL05770221 T PL 05770221T PL 05770221 T PL05770221 T PL 05770221T PL 1791820 T3 PL1791820 T3 PL 1791820T3
Authority
PL
Poland
Prior art keywords
quinoline derivatives
enantioselective preparation
enantioselective
preparation
quinoline
Prior art date
Application number
PL05770221T
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1791820(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1791820T3 publication Critical patent/PL1791820T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL05770221T 2004-06-22 2005-06-21 Sposób enancjoselektywnego wytwarzania pochodnych chinoliny PL1791820T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds
PCT/EP2005/006686 WO2005123684A2 (en) 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative
EP05770221A EP1791820B1 (en) 2004-06-22 2005-06-21 Enantioselective preparation of quinoline derivatives

Publications (1)

Publication Number Publication Date
PL1791820T3 true PL1791820T3 (pl) 2010-05-31

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05770221T PL1791820T3 (pl) 2004-06-22 2005-06-21 Sposób enancjoselektywnego wytwarzania pochodnych chinoliny

Country Status (32)

Country Link
US (2) US20090054653A1 (pl)
EP (1) EP1791820B1 (pl)
JP (1) JP5064214B2 (pl)
KR (1) KR101179302B1 (pl)
CN (1) CN1968927B (pl)
AR (2) AR049553A1 (pl)
AT (1) ATE450512T1 (pl)
AU (1) AU2005254698B2 (pl)
BR (1) BRPI0512298A (pl)
CA (1) CA2566388C (pl)
CY (1) CY1109884T1 (pl)
DE (1) DE602005018076D1 (pl)
DK (1) DK1791820T3 (pl)
EC (1) ECSP067100A (pl)
ES (1) ES2337273T3 (pl)
GB (1) GB0413960D0 (pl)
HR (1) HRP20100087T1 (pl)
IL (1) IL179600A (pl)
MA (1) MA28687B1 (pl)
MX (1) MXPA06014695A (pl)
MY (1) MY142051A (pl)
NO (1) NO339079B1 (pl)
NZ (1) NZ551276A (pl)
PE (1) PE20060304A1 (pl)
PL (1) PL1791820T3 (pl)
PT (1) PT1791820E (pl)
RU (1) RU2383534C2 (pl)
SI (1) SI1791820T1 (pl)
TN (1) TNSN06408A1 (pl)
TW (1) TWI347317B (pl)
WO (1) WO2005123684A2 (pl)
ZA (1) ZA200609257B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198450B2 (en) 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
WO2011056929A1 (en) 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
BR112013000946B1 (pt) 2010-07-14 2020-09-08 Novartis Ag Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
EP3138837B1 (en) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Indacaterol free base in solid form
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
ES2637719T3 (es) 2013-02-13 2017-10-16 Novartis Ag Compuestos heterocíclicos agonistas del receptor IP
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
WO2014141069A1 (en) 2013-03-14 2014-09-18 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP3205646A3 (en) 2013-03-27 2017-10-04 Laboratorios Lesvi, S.L. Intermediates for the manufacture of (r)-5-[2- (5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one (indacaterol)
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
EP3022201A1 (en) 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
ES2815123T3 (es) 2014-01-09 2021-03-29 Davuluri Ramamohan Rao Proceso novedoso para la preparación de indacaterol o sus sales aceptables farmacéuticamente
WO2015145353A1 (en) 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
JP6621442B2 (ja) * 2016-05-17 2019-12-18 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 金属イオンバッテリー
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN114591236A (zh) * 2020-12-02 2022-06-07 四川海思科制药有限公司 一种茚达特罗的改进制备方法
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones

Also Published As

Publication number Publication date
CN1968927B (zh) 2010-07-21
JP2008503526A (ja) 2008-02-07
GB0413960D0 (en) 2004-07-28
CA2566388C (en) 2013-04-16
ECSP067100A (es) 2007-01-26
CN1968927A (zh) 2007-05-23
CA2566388A1 (en) 2005-12-29
RU2383534C2 (ru) 2010-03-10
HK1105121A1 (en) 2008-02-01
DK1791820T3 (da) 2010-04-06
EP1791820A2 (en) 2007-06-06
SI1791820T1 (sl) 2010-04-30
KR101179302B1 (ko) 2012-09-03
AR082981A2 (es) 2013-01-23
AU2005254698A1 (en) 2005-12-29
NZ551276A (en) 2010-06-25
TWI347317B (en) 2011-08-21
CY1109884T1 (el) 2014-09-10
HRP20100087T1 (hr) 2010-06-30
MA28687B1 (fr) 2007-06-01
AR049553A1 (es) 2006-08-16
EP1791820B1 (en) 2009-12-02
PE20060304A1 (es) 2006-05-19
MXPA06014695A (es) 2007-02-12
RU2007102228A (ru) 2008-07-27
DE602005018076D1 (de) 2010-01-14
KR20070029752A (ko) 2007-03-14
NO339079B1 (no) 2016-11-07
IL179600A (en) 2011-11-30
MY142051A (en) 2010-08-30
TNSN06408A1 (en) 2008-02-22
ZA200609257B (en) 2008-07-30
NO20070400L (no) 2007-03-21
ATE450512T1 (de) 2009-12-15
BRPI0512298A (pt) 2008-03-25
JP5064214B2 (ja) 2012-10-31
TW200615265A (en) 2006-05-16
AU2005254698B2 (en) 2008-09-25
WO2005123684A2 (en) 2005-12-29
US20120220775A1 (en) 2012-08-30
WO2005123684A3 (en) 2006-06-01
US20090054653A1 (en) 2009-02-26
PT1791820E (pt) 2010-02-23
ES2337273T3 (es) 2010-04-22
IL179600A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
SI1791820T1 (sl) Enantioselektivna priprava kinolinskih derivatov
SI1802579T1 (sl) Derivati 3-arilaminopiridina
ZA200603657B (en) Novel quinoline derivatives
IL195724A0 (en) Stable laquinimod preparations
IL181587A0 (en) Production of ??-abeta
IL176715A0 (en) Substituted quinoline compounds
GB0421149D0 (en) Preparation of oxycodone
AP2006003837A0 (en) Irinotecan preparation
IL182800A0 (en) Formulations of[1,4]diazepino[6,7,1-ij]quinoline derivatives
PL1912647T3 (pl) Pochodne chinoliny jako środki antybakteryjne
IL190865A0 (en) Formulations of quinolinones
ZA200703695B (en) Treatment of mastitis with enrofloxacin
EP1912499A4 (en) PREPARATION OF MONTELUKAST
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
PL1928887T3 (pl) Sposoby otrzymywania analogów chinolonowych
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
TWI340650B (en) Amine saly of carbostyril derivative
IL177647A0 (en) Use of enzyme
ZA200803213B (en) Formulations of quinolinones
ZA200605575B (en) Substituted quinoline compounds
GB0409250D0 (en) Preparation of cabergoline
HK1123207A (en) Formulations of quinolinones
GB0428061D0 (en) Novel Quinoline Compounds
HK1100023A (en) Isoquinoline derivatives and methods of use thereof
AU2004901586A0 (en) Novel derivatives of biomolecules